The U.S. International Trade Commission (ITC) finally gave Medytox a hand in the final judgment on the lawsuit for infringement of trade secrets of botulinum strains of Medytox and Daewoong Pharmaceutical.
The US ITC Committee said on the 16th (local time) that "Daewoong Pharmaceutical's botulinum toxin formulation'Nabota' (U.S. product name bulletin) violated Article 337 of the Customs Act and ordered a ban on imports in the US for 21 months (Photo = Getty Image Korea) The final decision was made.
The two companies are struggling over the source of the botulinum strain, the raw material for a botulinum toxin formulation called'Botox'.
Medytox and Daewoong Pharmaceuticals have botulinum toxin formulations'Meditoxin' and'Nabota', respectively.
Medytox reported that Daewoong Pharmaceutical had stolen its strain and manufacturing process technical documents, and filed a formal complaint with ITC for infringement of trade secrets early last year.
ITC reported that Daewoong Pharmaceutical infringed Medytox's trade secrets in a preliminary judgment in July and recommended that Nabota should be banned for 10 years.
(Photo = Yonhap News TV, Yonhap News)